Scoop: No­var­tis’ re­treat on CAR-T in­cludes ax­ing most of its se­nior ex­ecs on the team

Us­man “Oz” Azam

No­var­tis’ plan to pull back on CAR-T in­cludes purg­ing most of the se­nior ex­ecs in­volved in the project, sig­nal­ing the phar­ma gi­ant’s R&D re­treat is more ex­ten­sive than the com­pa­ny has want­ed to ad­mit so far.

End­points News, which broke the sto­ry on No­var­tis’ sur­pris­ing R&D move, ini­tial­ly ob­tained the top frag­ment of an in­ter­nal cor­po­rate memo au­thored by Us­man “Oz” Azam at No­var­tis spelling out that the com­pa­ny is dis­solv­ing its cell and gene ther­a­py unit re­spon­si­ble for its pi­o­neer­ing work on CAR-T. Now we have the rest of it, and it in­cludes this on the team ex­ecs:

Un­for­tu­nate­ly a num­ber of col­leagues will be im­pact­ed by this change as many po­si­tions are be­ing elim­i­nat­ed. Im­pact­ed US-based as­so­ciates are be­ing no­ti­fied in meet­ings to­day. As­so­ci­ates based in Basel will learn more about their in­di­vid­ual cir­cum­stances on Thurs­day. The ma­jor­i­ty of the CG­TU Lead­er­ship Team mem­bers, who are among the best I have worked with, are al­so im­pact­ed.

Ear­li­er in the week, No­var­tis por­trayed the de­ci­sion to in­te­grate the unit in­to its on­col­o­gy di­vi­sion as an ef­fi­cien­cy move, some­thing No­var­tis does on a reg­u­lar ba­sis. The com­pa­ny, a spokesper­son not­ed, would con­tin­ue to work in the field and “with a new in­te­grat­ed de­vel­op­ment mod­el, we can ef­fi­cient­ly ad­vance our work on CART as part of our fo­cus in im­muno-on­col­o­gy by rein­te­grat­ing the func­tions.”

Elim­i­nat­ing the ex­ec­u­tive team un­der­scores con­cerns that No­var­tis, one of the three key lead­ers in CAR-T, along with Kite and Juno, is step­ping away just as the first CAR-T ther­a­pies are near­ing ap­proval. And No­var­tis has said that it will con­tin­ue to push its lead pro­gram CTL019 in pe­di­atric r/r ALL to the FDA in ear­ly 2017 and the EMA lat­er in 2017.

Just two years ago, in a Forbes cov­er sto­ry, No­var­tis CEO Joe Jimenez vowed to pur­sue CAR-T with a no-ex­pens­es-spared ap­proach to cur­ing can­cer. But how se­ri­ous can it be about CAR-T when the se­nior team lead­ers are be­ing axed as part of a move to elim­i­nate 120 jobs out of the 400 af­fect­ed?

I asked No­var­tis rep­re­sen­ta­tives that ques­tion ear­ly Fri­day, but have yet to hear back. (Up­date: Here’s their re­sponse.)

Azam goes on at one point to as­sure the 400-mem­ber group, many of whom were about to be axed, that “We have led the in­dus­try in trans­form­ing the prac­tice of med­i­cine with CART ther­a­py…the clin­i­cal and reg­u­la­to­ry teams will move to Glob­al Drug De­vel­op­ment and specif­i­cal­ly On­col­o­gy Glob­al De­vel­op­ment, and our col­leagues who are sup­port­ing com­mer­cial readi­ness will move to the On­col­o­gy or­ga­ni­za­tion.”

Here is the en­tire memo ob­tained by End­points:

Dear Col­leagues,

I still vivid­ly re­mem­ber the mo­ment that David Ep­stein in­vit­ed me to lead a new Unit ded­i­cat­ed to Cell & Gene Ther­a­pies. It was a mix­ture of ex­cite­ment and fear – a feel­ing that fu­els my en­tre­pre­neur­ial spir­it, and one that so many of you share. The risk of em­bark­ing on a new ad­ven­ture in un­chart­ed ter­ri­to­ry is that things don’t al­ways work out how you en­vi­sioned. To­day, I have the un­for­tu­nate task of an­nounc­ing that we are dis­solv­ing the Cell & Gene Ther­a­pies Unit. The ad­ven­ture start­ed years ago with the ini­ti­a­tion of the Penn col­lab­o­ra­tion. Af­ter rec­og­niz­ing the unique­ness of this ther­a­py, the or­ga­ni­za­tion im­ple­ment­ed our CG­TU de­sign struc­ture to bring to­geth­er bright minds in dis­parate func­tions from across No­var­tis to act as a SWAT team and fig­ure out how to make this a suc­cess. And we did. In the space of two years we com­plet­ed an un­prece­dent­ed tech trans­fer of CAR tech­nol­o­gy to a com­mer­cial-grade, GMP qual­i­ty, scal­able man­u­fac­tur­ing site in Mor­ris Plains, gained clar­i­ty on the in­di­ca­tions with the great­est ben­e­fit/risk pro­file, ini­ti­at­ed and ful­ly en­rolled two glob­al mul­ti-site clin­i­cal tri­als in two dif­fer­ent in­di­ca­tions, and laid the ground­work for the evo­lu­tion of fu­ture cell pro­cess­ing. But most im­por­tant­ly, as Kathy says, we saved the lives of sev­er­al kinder­garten class­es and dozens of par­ents and grand­par­ents.

We have led the in­dus­try in trans­form­ing the prac­tice of med­i­cine with CART ther­a­py.

While we were fo­cused on cell and gene ther­a­pies, the larg­er No­var­tis or­ga­ni­za­tion con­tin­ued to evolve. We el­e­vat­ed the role of On­col­o­gy, we have in­te­grat­ed our glob­al de­vel­op­ment func­tion, and we are op­er­at­ing, more than ever, as one No­var­tis. This is the time to re-in­te­grate the Unit back to the func­tions. We have grown, the or­ga­ni­za­tion has grown, and it’s time to come back to­geth­er. An in­te­grat­ed Mor­ris Plains foot­print in­clud­ing Tech Ops, Qual­i­ty and IT process de­vel­op­ment will move un­der BT­DM, the clin­i­cal and reg­u­la­to­ry teams will move to Glob­al Drug De­vel­op­ment and specif­i­cal­ly On­col­o­gy Glob­al De­vel­op­ment, and our col­leagues who are sup­port­ing com­mer­cial readi­ness will move to the On­col­o­gy or­ga­ni­za­tion.

Un­for­tu­nate­ly a num­ber of col­leagues will be im­pact­ed by this change as many po­si­tions are be­ing elim­i­nat­ed. Im­pact­ed US-based as­so­ciates are be­ing no­ti­fied in meet­ings to­day. As­so­ci­ates based in Basel will learn more about their in­di­vid­ual cir­cum­stances on Thurs­day. The ma­jor­i­ty of the CG­TU Lead­er­ship Team mem­bers, who are among the best I have worked with, are al­so im­pact­ed.

I know this news may be dif­fi­cult, and I know you have ques­tions. I would like to elab­o­rate on what I have shared here in a Town Hall this af­ter­noon at 15:00 CET/3:00 PM EDT. I know this is short no­tice, so we have arranged many ways for you to con­nect from mul­ti­ple time zones. We have booked rooms in East Hanover, Mor­ris Plains (where I will be) and Cam­bridge, or you can di­al in via We­b­cast or tele­con­fer­ence if you would like to hear more. A meet­ing in­vi­ta­tion will fol­low.

Illustration: Assistant Editor Kathy Wong for Endpoints News

As mon­ey pours in­to dig­i­tal ther­a­peu­tics, in­sur­ance cov­er­age crawls



Talk therapy didn’t help Lily with attention deficit hyperactivity disorder, or ADHD. But a video game did.

As the 10-year-old zooms through icy waters and targets flying creatures on the snow-capped planet Frigidus, she builds attention skills, thanks to Akili Interactive Labs’ video game EndeavorRx. She’s now less anxious and scattered, allowing her to stay on a low dose of ADHD medication, according to her mom Violet Vu.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Up­dat­ed: FDA re­mains silent on or­phan drug ex­clu­siv­i­ty af­ter last year's court loss

Since losing a controversial court case over orphan drug exclusivity last year, the FDA’s Office of Orphan Products Development has remained entirely silent on orphan exclusivity for any product approved since last November, leaving many sponsors in limbo on what to expect.

That silence means that for more than 70 orphan-designated indications for more than 60 products, OOPD has issued no public determination on the seven-year orphan exclusivity in the Orange Book, and no new listings of orphan exclusivity appear in OOPD’s searchable database, as highlighted recently by George O’Brien, a partner in Mayer Brown’s Washington, DC office.

Eli Lil­ly’s Alzheimer’s drug clears more amy­loid ear­ly than Aduhelm in first-ever head-to-head. Will it mat­ter?

Ahead of the FDA’s decision on Eli Lilly’s Alzheimer’s drug donanemab in February, the Big Pharma is dropping a first cut of data from one of the more interesting trials — but less important in a regulatory sense — at an Alzheimer’s conference in San Francisco.

In the unblinded 148-person study, Eli Lilly pitted its drug against Aduhelm, Biogen’s drug that won FDA approval but lost Medicare coverage outside of clinical trials. Notably, the study didn’t look at clinical outcomes, but rather the clearance of amyloid, a protein whose buildup is associated with Alzheimer’s disease, in the brain.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 153,900+ biopharma pros reading Endpoints daily — and it's free.

Ei­sai’s ex­pand­ed Alzheimer’s da­ta leave open ques­tions about safe­ty and clin­i­cal ben­e­fit

Researchers still have key questions about Eisai’s investigational Alzheimer’s drug lecanemab following the publication of more Phase III data in the New England Journal of Medicine Tuesday night.

In the paper, which was released in conjunction with presentations at an Alzheimer’s conference, trial investigators write that a definition of clinical meaningfulness “has not been established.” And the relative lack of new information, following topline data unveiled in September, left experts asking for more — setting up a potential showdown to precisely define how big a difference the drug makes in patients’ lives.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Matt Gline, Roivant Sciences CEO (Photo by John Sciulli/Getty Images for GLG)

Pfiz­er and Roivant team up again for an­oth­er 'Van­t', set­ting up an­ti-in­flam­ma­to­ry show­down with Prometheus

Pfizer and Roivant are teaming up to launch a new ‘Vant’ aimed at bringing a mid-stage anti-inflammatory drug to market, the pair announced Thursday.

There’s no name for the startup yet, nor are there any employees. Thus far, the new company and Roivant can be considered “one and the same,” Roivant CEO Matt Gline tells Endpoints News. But Pfizer is so enthusiastic about the target that it elected to keep 25% of equity in the drug rather than take upfront cash from Roivant, Gline said.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 153,900+ biopharma pros reading Endpoints daily — and it's free.

Roche HQ in Basel, Switzerland. (Image credit: Kyle LaHucik/Endpoints News)

As com­peti­tors near FDA goal­post, Roche spells out its re­peat Alzheimer's set­back

Before Roche can turn all eyes on a new version of its more-than-once-failed Alzheimer’s drug gantenerumab, the Big Pharma had to flesh out data on the November topline failure at an annual conference buzzier than in years past thanks to hotly watched rivals in the field: Eisai and Biogen’s lecanemab, and Eli Lilly’s donanemab.

There was less than a 10% difference between Roche’s drug and placebo at slowing cognitive decline across two Phase III trials, which combined enrolled nearly 2,000 Alzheimer’s patients. In its presentation at the conference Wednesday, Roche said it saw less sweeping away of toxic proteins than it had anticipated. For years, researchers and investors have put their resources behind the idea that more amyloid removal would equate to reduced cognitive decline.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 153,900+ biopharma pros reading Endpoints daily — and it's free.

SQZ Biotech slash­es head­count by 60% as founder/CEO hits ex­it — while Syn­log­ic lays off 25%

It’s a tough time for early-stage companies developing highly promising, but largely unproven, new technologies.

Just ask SQZ Biotechnologies and Synlogic. The former is bidding farewell to its founder and CEO and slashing the headcount by 60% as it pivots from its original cell therapy platform to a next-gen approach; the latter — a synthetic biology play founded by MIT’s Jim Collins and Tim Lu — is similarly “optimizing” the company to focus on lead programs. The resulting realignment means 25% of the staffers will be laid off.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 153,900+ biopharma pros reading Endpoints daily — and it's free.

Lynn Baxter, Viiv Healthcare's head of North America

Vi­iV dri­ves new cor­po­rate coali­tion in­clud­ing Uber, Tin­der and Wal­mart, aimed at end­ing HIV

ViiV Healthcare is pulling together an eclectic coalition of consumer businesses in a new White House-endorsed effort to end HIV by the end of the decade.

The new US Business Action to End HIV includes pharma and health companies — Gilead Sciences, CVS Health and Walgreens — but extends to a wide range of consumer companies that includes Tinder, Uber and Walmart.

ViiV is the catalyst for the group, plunking down more than half a million dollars in seed money and taking on ringmaster duties for launch today on World AIDS Day, but co-creator Health Action Alliance will organize joint activities going forward. ViiV and the alliance want and expect more companies to not only join the effort, but also pitch in funding.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 153,900+ biopharma pros reading Endpoints daily — and it's free.

Paul Hudson, Sanofi CEO (Romuald Meigneux/Sipa via AP Images)

Sanofi and DN­Di aim to elim­i­nate sleep­ing sick­ness in Africa with promis­ing Ph II/III re­sults for new drug

The Drugs for Neglected Diseases initiative (DNDi) and Sanofi today said that their potential sleeping sickness treatment saw success rates of up to 95% from a Phase II/III study investigating the safety and efficacy of single-dose acoziborole.

The potentially transformative treatment for sleeping sickness would mainly be targeted at African countries, according to data published today in The Lancet Infectious Diseases medical journal. The clinical trial was led by DNDi and its partners in the Democratic Republic of the Congo (DRC) and Guinea, with the authors noting: